View in EDS

DDX5 (p68) and UbE2T as emerging superior cancer therapeutic targets: dual molecular glue target degradation by FL118 for conquering difficult-to-treat cancers.

Saved in:
Bibliographic Details
Title: DDX5 (p68) and UbE2T as emerging superior cancer therapeutic targets: dual molecular glue target degradation by FL118 for conquering difficult-to-treat cancers.
Authors: Li F; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. fengzhi.li@roswellpark.org.; Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. fengzhi.li@roswellpark.org.; Pancreatic Cancer Research Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. fengzhi.li@roswellpark.org.; Canget BioTekpharma LLC, Buffalo, NY, 14203, USA. fengzhi.li@roswellpark.org., Ling X; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Canget BioTekpharma LLC, Buffalo, NY, 14203, USA., Chakraborty S; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Pancreatic Cancer Research Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Tang DG; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., McLean K; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Department of Gynecology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Wu W; Canget BioTekpharma LLC, Buffalo, NY, 14203, USA., Sule N; Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Vadehra D; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Fountzilas C; Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Pancreatic Cancer Research Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Gupta A; Department of Pediatrics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Twist C; Department of Pediatrics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Ohm J; Department of Cancer Genetics & Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Chatta G; Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Abrams SI; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Tumor Immunology & Immunotherapy Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
Source: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2026 May 18; Vol. 45 (1). Date of Electronic Publication: 2026 May 18.
Publication Type: Journal Article; Review
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-9966 (Electronic) Linking ISSN: 03929078 NLM ISO Abbreviation: J Exp Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42152107
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: DDX5 (p68) and UbE2T as emerging superior cancer therapeutic targets: dual molecular glue target degradation by FL118 for conquering difficult-to-treat cancers.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Li+F%22">Li F</searchLink>; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. fengzhi.li@roswellpark.org.; Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. fengzhi.li@roswellpark.org.; Pancreatic Cancer Research Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. fengzhi.li@roswellpark.org.; Canget BioTekpharma LLC, Buffalo, NY, 14203, USA. fengzhi.li@roswellpark.org.<br /><searchLink fieldCode="AU" term="%22Ling+X%22">Ling X</searchLink>; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Canget BioTekpharma LLC, Buffalo, NY, 14203, USA.<br /><searchLink fieldCode="AU" term="%22Chakraborty+S%22">Chakraborty S</searchLink>; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Pancreatic Cancer Research Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.<br /><searchLink fieldCode="AU" term="%22Tang+DG%22">Tang DG</searchLink>; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.<br /><searchLink fieldCode="AU" term="%22McLean+K%22">McLean K</searchLink>; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Department of Gynecology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.<br /><searchLink fieldCode="AU" term="%22Wu+W%22">Wu W</searchLink>; Canget BioTekpharma LLC, Buffalo, NY, 14203, USA.<br /><searchLink fieldCode="AU" term="%22Sule+N%22">Sule N</searchLink>; Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.<br /><searchLink fieldCode="AU" term="%22Vadehra+D%22">Vadehra D</searchLink>; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.<br /><searchLink fieldCode="AU" term="%22Fountzilas+C%22">Fountzilas C</searchLink>; Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Pancreatic Cancer Research Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.<br /><searchLink fieldCode="AU" term="%22Gupta+A%22">Gupta A</searchLink>; Department of Pediatrics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.<br /><searchLink fieldCode="AU" term="%22Twist+C%22">Twist C</searchLink>; Department of Pediatrics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.<br /><searchLink fieldCode="AU" term="%22Ohm+J%22">Ohm J</searchLink>; Department of Cancer Genetics & Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.<br /><searchLink fieldCode="AU" term="%22Chatta+G%22">Chatta G</searchLink>; Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.<br /><searchLink fieldCode="AU" term="%22Abrams+SI%22">Abrams SI</searchLink>; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Tumor Immunology & Immunotherapy Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228308647%22">Journal of experimental & clinical cancer research : CR</searchLink> [J Exp Clin Cancer Res] 2026 May 18; Vol. 45 (1). <i>Date of Electronic Publication: </i>2026 May 18.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BioMed+Central%22">BioMed Central </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>8308647 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1756-9966 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203929078%22">03929078 </searchLink><i>NLM ISO Abbreviation: </i>J Exp Clin Cancer Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42152107
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s13046-026-03733-3
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: DDX5 (p68) and UbE2T as emerging superior cancer therapeutic targets: dual molecular glue target degradation by FL118 for conquering difficult-to-treat cancers.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Li F
      – PersonEntity:
          Name:
            NameFull: Ling X
      – PersonEntity:
          Name:
            NameFull: Chakraborty S
      – PersonEntity:
          Name:
            NameFull: Tang DG
      – PersonEntity:
          Name:
            NameFull: McLean K
      – PersonEntity:
          Name:
            NameFull: Wu W
      – PersonEntity:
          Name:
            NameFull: Sule N
      – PersonEntity:
          Name:
            NameFull: Vadehra D
      – PersonEntity:
          Name:
            NameFull: Fountzilas C
      – PersonEntity:
          Name:
            NameFull: Gupta A
      – PersonEntity:
          Name:
            NameFull: Twist C
      – PersonEntity:
          Name:
            NameFull: Ohm J
      – PersonEntity:
          Name:
            NameFull: Chatta G
      – PersonEntity:
          Name:
            NameFull: Abrams SI
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 18
              M: 05
              Text: 2026 May 18
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1756-9966
          Numbering:
            – Type: volume
              Value: 45
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Journal of experimental & clinical cancer research : CR
              Type: main
ResultId 1